Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS.

Slides:



Advertisements
Similar presentations
What Are We Referring to When We State PTH Level?.
Advertisements

Ca++, PO4, PTH & VIT D Calcium, Phosphorus & Vitamin D
Got Calcium? Ca 2+. Plasma Calcium Regulation Plasma calcium totals 2.4 mM (9.4 mg/dl) –Free calcium is 1.2 mM.
Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Hormonal regulation of calcium and phosphorus homeostasis.
MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Management of hyperphosphataemia of chronic kidny disease Presented by Pharmacist/ Eman Youssif 1.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Calcium homeostasis. Bone remodeling and repair Continuous remodeling –5 to 7 % of total bone mass per week –Critical for maintenance of proper structure.
Endocrine Regulation of Calcium and Phosphate Metabolism
Nephrology Grand Rounds 5/13/08. Refractory Hyperparathyroidism Brad Weaver.
PARATHYROID HORMONE, HYPERPARATHYROIDISM CKD, & PTH ASSAYS David Plaut & Shanti Narayanan Summer, 2012.
Hyperparathyroidism.
Calcium & Inorganic phosphate. Calcium Physiological function : Bone mineralization Blood coagulation Important in muscle contraction Affecting enzyme.
CALCIUM AND PHOSPHATE HOMEOSTASIS. Organs: Parathyroid Four oval masses on posterior of thyroid gland Develops from the 3 rd and 4 th pharyngeal pouches.
Metabolic Bone Diseases METAOLC BONE DISEASES are diseases of bones caused by disturbances in metabolism of bones in metabolism of bones & is characterized.
Hypercalcemia Hypocalcemia
By Dr. Sana Fatima Instructor, Biochemistry Department.
Vitamin D Dr.S.Chakravarty ,MD.
CALCIUM HOMEOSTASIS Dr. Sumbul Fatma. Calcium Homeostasis Falling.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
Chronic Kidney Disease-Mineral and Bone Disorder
Pharmacology of drugs used in calcium & vitamin D disorders
Vitamin D, Rickets and Osteoporosis
DRUGS THAT AFFECT BONE MINERAL HOMEOSTASIS
Copyright © 2006 by Elsevier, Inc. Microscopic Appearance of the Thyroid Gland Figure 76-1; Guyton & Hall.
﴿و ما أوتيتم من العلم إلا قليلا﴾
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
Pharmacology of drugs used in calcium & vitamin D disorders
Lecture # 12: Calcium homeostasis
Parathyroid disorders
R R R R C C OSTEOPOROSIS R heumatology R esearch C enter INTERNAL MEDICINE CONGRESS 1382.
PARATHYROID HORMONE (PTH). SOURCE SYNTHESIS 1. Preprohormone=110 A.A. 2. Prohormone= 90 A.A. 3. Hormone= 84 A.A.( Mol.wt.=9500)
Milk-Alkali Syndrome and Evaluation of Hypercalcemia Morning Report 8/18/2009 TJ O’Neill.
Adult Medical-Surgical Nursing Musculo-skeletal Module: Osteomalacia.
Biochemical Test Serum Calcium
PTH Calcitonin 10mg% Vitamin D Lecture 52 Ca++ Homeostasis
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
( Source, Release & Function ) 1.structure of bone & teeth 6. hormone secretion 5. hormonal actions 2.neurotransmission 4. muscle contraction 3. blood.
Vitamin D, Rickets and Osteoporosis
METABOLIC BONE DISEASES Amro Al-Hibshi, MD, FRCSC, MEd.
Parathyroid Gland & Calcium Metabolism
Agents that Affect Bone Mineral Homeostasis Agents that Affect Bone Mineral Homeostasis By Dr. Sasan Zaeri (PharmD, PhD) (PharmD, PhD) Department of Pharmacology.
Calcium, Phosphorus, Magnesium and Related Disorders (By Basil OM Saleh) Objective: 1. Calcium & Phosphorus homeostasis, Hypercalcaemia, and Hypocalcaemia.
What we are missing 2012 KDIGO guideline. Anemia.
Parathyroid hormone(Parathormone) Lecture NO: 2nd MBBS
Calcitonin Calcitonin By: Narjes lavasani.
Endocrine Disorders Parathyroid Gland
Volume 79, Pages S3-S8 (April 2011)
Drugs Affecting Calcium Levels and Bone Mineralization
Bone Metabolism MSS/Biochemistry, fall-2017
Responses to reduced plasma calcium concentration
Post Menopausal Osteoporosis
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Volume 67, Pages S1-S7 (June 2005)
Acute and Chronic Renal Failure
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Clinical Chemistry of Parathyroid disorders
Volume 73, Issue 1, Pages 3-5 (January 2008)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
The major function of the parathyroid glands is to maintain the body's calcium level within a very narrow range, so that the nervous and muscular systems.
Volume 79, Pages S3-S8 (April 2011)
Parathyroid hormone(Parathormone) Lecture NO: 2nd MBBS
Circulating PTH molecular forms: What we know and what we don't
Osteoblasts Osteocytes Osteoclasts Cells of Bone Osteoblasts Osteocytes Osteoclasts.
Volume 71, Issue 8, Pages (April 2007)
Mineral metabolism in CKD: adaptation devolves into maladaptation.
Presentation transcript:

Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS

56 Y/O man on regular hemodialysis is transferred to another dialysis center. Previous records showing values from the past year are as following. In new dialysis center he is continued on the same dialysis regimen. New chemistry values are as following: Ca: 9P: 5.4 PTH: 610Alk Pho: 112

The sudden increase in PTH is likely due to which one of the following?  A: Lower dialyzate calcium  B: Pt noncompliance  C: Progression of hyperparathyroidism  D: A change in PTH assay  E: Access insufficiency

FGF – 23 Produced by Osteocyte (Osteoblast)  Decreases renal phosphate reabsorption  Decreases the production of 1.25 DH Vit D  In CRF phosphate retention many result progressive increase in FGF-23 level and finally results hyperparathyroidism.

FGF – 23 as an adaptive mechanism (trade off) FGF-23 level increases to maintain normal serum phosphate while decreasing Vit D level as initial trigger for hyperparathyroidism. FGF-23 levels are also an independent risk factor of LV hypertrophy.

PTH PTH a polypeptide of 84 amino acids is secreted in response to hypocalcemia with a half life of few minutes. Stimulating osteoclast and bone resorption Renal reabsorption of Ca Renal excretion of P Stimulates synthesis of Vit D Increases Intestinal absorption of Ca

PTH exerts its biological effects through the first 34 (N-terminal) amino acids,which binds to the type I PTH receptor. The cacboxyl © terminal (last 50 aa,) has no direct influence on PTH receptor.

PTH Fragments Accumulated in CKD patients. (7-84)fragment is the largest proportion of non PTH (1-84) fragment (80% of circulation PTH) (7- 84) fragment exerts opposite biological effect on bone compared with (1-84) PTH

Clinical Importance of PTH (1-84) and (7- 84) fragment PTH (1- 84)PTH (7- 84) Stimulates bone resorption to increase serum Ca produced in response to hypercalcemia Stimulates activity of 1, 25 Vit D High serum level in CKD due to decreased excretion Decreases serum POpposite effects to PTH (1- 84) Stimulates bone formation through a G-protein receptorsHalf life times PTH (1- 84) Half life 2- 4 min

First Generation of RIAs for PTH  Directed Ab against c-terminal  Directed Ab against N- terminal

Limitations of First Generation RIA  Measures both PTH (1- 84) & PTH fragment  Overestimates PTH level  Inaccurate estimation of PTH due to impaired renal excretion  Poor sensitivity at low concentration  Not highly reliable

PTH Assay 2 nd Generation Immunometric assay (IMAs) of intact PTH Dose not measure C- terminal or mid fragment. iPTH assay brings advantages over RIAs but is associated with several limitations  Overestimates PTH in CKD  Limited sensitivity & specificity for assessing bone turnover in CKD patients.

3 rd generation of PTH assay (IMAs) Elecys PTH (1-84) Immunometric assay of whole PTH (1- 84)  Anti-C-terminal Ab  Anti- N- terminal Ab  Does not measure PTH (7- 84)  No over estimation of PTH level

Advantages  High specificity & sensitivity for PTH (1- 84)  % lower serum level  Intera surgical Diagnosis of resection sufficiency Limitation: Not yet widely available

Bone mineral density: BMD is measured by dual energy x-ray absorptomety in general population. BMD is lower in CKD than a GP. The utility of this test in CKD is limited.

Other Indicators of BMD  Vit K activity correlates with BMD & risk of Fx  Possible efficacy & safety of Vit K supplement in dialysis patients has not yet been documented to reduce Fx  Bone morphogenic protein- 7

The gold standard test for DX the various types of bone disease in CKD patients but it is an invasive test which is recommended in following conditions : Unexplained FX Unexplained hypercalcemia Unexplained hyperphosphatemia Persistant bone pain Possible aluminum toxicity Before therapy with biphosphonate Bone Biopsy